Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2-T cells.

de Bruin RCG, Veluchamy JP, Lougheed SM, Schneiders FL, Lopez-Lastra S, Lameris R, Stam AG, Sebestyen Z, Kuball J, Molthoff CFM, Hooijberg E, Roovers RC, Santo JPD, van Bergen En Henegouwen PMP, Verheul HMW, de Gruijl TD, van der Vliet HJ.

Oncoimmunology. 2017 Oct 20;7(1):e1375641. doi: 10.1080/2162402X.2017.1375641. eCollection 2017.

2.

The effects of systemic treatment with aminobisphosphonates and statins on circulating Vγ9Vδ2-T cells in patients with advanced cancer.

Schneiders FL, Huijts CM, Reijm M, Bontkes HJ, Verheul HMW, de Gruijl TD, van der Vliet HJ.

Immunobiology. 2018 Feb;223(2):171-177. doi: 10.1016/j.imbio.2017.10.029. Epub 2017 Oct 16.

PMID:
29055564
3.

mTOR Inhibition Per Se Induces Nuclear Localization of FOXP3 and Conversion of Invariant NKT (iNKT) Cells into Immunosuppressive Regulatory iNKT Cells.

Huijts CM, Schneiders FL, Garcia-Vallejo JJ, Verheul HM, de Gruijl TD, van der Vliet HJ.

J Immunol. 2015 Sep 1;195(5):2038-45. doi: 10.4049/jimmunol.1402710. Epub 2015 Aug 3.

4.

Vγ9Vδ2-T cells as antigen presenting cells for iNKT cell based cancer immunotherapy.

Werter IM, Schneiders FL, Scotet E, Verheul HM, de Gruijl TD, van der Vliet HJ.

Oncoimmunology. 2014 Dec 8;3(9):e955343. eCollection 2014 Oct.

5.

Aminobisphosphonates inhibit dendritic cell-mediated antigen-specific activation of CD1d-restricted iNKT cells.

Schneiders FL, Huijts CM, Mantici A, Menks MA, Scotet E, Veerhuis R, Verheul HM, de Gruijl TD, van der Vliet HJ.

Clin Immunol. 2015 May;158(1):92-9. doi: 10.1016/j.clim.2015.03.007. Epub 2015 Mar 18.

PMID:
25796193
6.

Arming the Melanoma Sentinel Lymph Node through Local Administration of CpG-B and GM-CSF: Recruitment and Activation of BDCA3/CD141(+) Dendritic Cells and Enhanced Cross-Presentation.

Sluijter BJ, van den Hout MF, Koster BD, van Leeuwen PA, Schneiders FL, van de Ven R, Molenkamp BG, Vosslamber S, Verweij CL, van den Tol MP, van den Eertwegh AJ, Scheper RJ, de Gruijl TD.

Cancer Immunol Res. 2015 May;3(5):495-505. doi: 10.1158/2326-6066.CIR-14-0165. Epub 2015 Jan 29.

7.

Bispecific antibody platforms for cancer immunotherapy.

Lameris R, de Bruin RC, Schneiders FL, van Bergen en Henegouwen PM, Verheul HM, de Gruijl TD, van der Vliet HJ.

Crit Rev Oncol Hematol. 2014 Dec;92(3):153-65. doi: 10.1016/j.critrevonc.2014.08.003. Epub 2014 Aug 20. Review.

PMID:
25195094
8.

CD1d-restricted antigen presentation by Vγ9Vδ2-T cells requires trogocytosis.

Schneiders FL, Prodöhl J, Ruben JM, O'Toole T, Scheper RJ, Bonneville M, Scotet E, Verheul HM, de Gruijl TD, van der Vliet HJ.

Cancer Immunol Res. 2014 Aug;2(8):732-40. doi: 10.1158/2326-6066.CIR-13-0167. Epub 2014 Apr 21.

9.

Exploiting the CD1d-iNKT cell axis for potentiation of DC-based cancer vaccines.

Lameris R, Schneiders FL, de Gruijl TD, van der Vliet HJ.

Methods Mol Biol. 2014;1139:155-65. doi: 10.1007/978-1-4939-0345-0_14.

PMID:
24619678
10.

An α-galactosylceramide nose job shapes up iNKT cells.

de Bruin RC, Schneiders FL, Santegoets SJ, Verheul HM, de Gruijl TD, van der Vliet HJ.

Immunotherapy. 2012 Jan;4(1):20-1. No abstract available.

PMID:
22263254
11.

Bulldozing β-linked glycolipids for recognition by invariant NKT cells.

de Bruin RC, Schneiders FL, Santegoets SJ, Verheul HM, de Gruijl TD, van der Vliet HJ.

Immunotherapy. 2012 Jan;4(1):20. No abstract available.

PMID:
22263253
12.

Circulating invariant natural killer T-cell numbers predict outcome in head and neck squamous cell carcinoma: updated analysis with 10-year follow-up.

Schneiders FL, de Bruin RC, van den Eertwegh AJ, Scheper RJ, Leemans CR, Brakenhoff RH, Langendijk JA, Verheul HM, de Gruijl TD, Molling JW, van der Vliet HJ.

J Clin Oncol. 2012 Feb 10;30(5):567-70. doi: 10.1200/JCO.2011.38.8819. Epub 2012 Jan 17. No abstract available.

PMID:
22253469
13.

Gram-positive bacteria: a major microbial ‘turn-on’ for invariant NKT cells.

de Bruin RC, Schneiders FL, Santegoets SJ, Verheul HM, de Gruijl TD, van der Vliet HJ.

Immunotherapy. 2012 Jan;4(1):19. doi: 10.2217/imt.11.152. No abstract available.

PMID:
22149997
14.

Activated iNKT cells promote Vγ9Vδ2-T cell anti-tumor effector functions through the production of TNF-α.

Schneiders FL, de Bruin RC, Santegoets SJ, Bonneville M, Scotet E, Scheper RJ, Verheul HM, de Gruijl TD, van der Vliet HJ.

Clin Immunol. 2012 Feb;142(2):194-200. doi: 10.1016/j.clim.2011.10.006. Epub 2011 Nov 4.

PMID:
22122798
15.

Nuancing the proposed role of NKT cells in aging.

Schneiders FL, de Bruin R, Exley MA, van der Vliet HJ.

Virulence. 2011 Mar-Apr;2(2):170; author reply 171. Epub 2011 Mar 1. No abstract available.

PMID:
21304268
16.

Clinical experience with α-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection.

Schneiders FL, Scheper RJ, von Blomberg BM, Woltman AM, Janssen HL, van den Eertwegh AJ, Verheul HM, de Gruijl TD, van der Vliet HJ.

Clin Immunol. 2011 Aug;140(2):130-41. doi: 10.1016/j.clim.2010.11.010. Epub 2010 Dec 18. Review.

PMID:
21169066
17.

Severe toxicity of capecitabine following uncomplicated treatment with 5-fluorouracil/leucovorin.

Schneiders FL, van den Berg HP, Peters GJ, Verheul HM, van der Vliet HJ.

Med Oncol. 2011 Dec;28(4):1136-9. doi: 10.1007/s12032-010-9598-9. Epub 2010 Jun 22.

PMID:
20567941

Supplemental Content

Loading ...
Support Center